Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The document serves as a transaction notification regarding insider trading activity rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction.
Material Changes and Transaction Details
The filing reports a purchase of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR). The specific details are as follows:
- Insider: Mr. J Ford, SVP and General Counsel.
- Transaction Type: Purchase of Ordinary Shares (ISIN: GB0009252882).
- Volume: 16,950 shares.
- Price: £13.200 per share.
- Date: February 4, 2021.
- Exchange: London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a statutory disclosure of a single transaction.
Investor Verification Points
- Verify the total number of shares held by Mr. J Ford following this transaction to assess overall insider ownership levels.
- Confirm the market price of GSK ordinary shares on February 4, 2021, to validate the transaction price of £13.200.
- Review subsequent filings to determine if this purchase was part of a broader insider trading pattern or a one-off event.